Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 89172

56 recalled-product records grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
December 06, 2021
Product types
Drug
Classifications
Class II
Statuses
Terminated
Recalling firm wording
Edge Pharma, LLC

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

56 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 56

ALUM Concentrate (Aluminum Potassium Sulfate Dodecahydrate in Sterile Water (PF) 30 g/300 ml, IV bag, Rx Only, Edge Pharma, LLC, 856 Hercules Dr, Colchester, VT 05446, NDC 05446-0637-03

D-0394-2022
Recall number
D-0394-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
30 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-25@2 12/08/2021 09-2021-08@1 12/23/2021 10-2021-20@3 02/01/2022

Distribution pattern

nationwide

drug · product 2 of 56

Lidocaine HCl Sterile Buffered Solution for Injection (PF) 1%, 10mL per syringe, Single Use Syringe for Infiltration and Nerve Block, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-0850-10

D-0395-2022
Recall number
D-0395-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
4465 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-27@3 12/09/2021 09-2021-24@1 01/06/2022 10-2021-14@2 01/31/2022

Distribution pattern

nationwide

drug · product 3 of 56

Lidocaine HCl/Epinephrine, Sterile Buffered Solution for Injection (PF) 1% / 1:100,000, 3 mL per syringe, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, (802) 992-1178, NDC 05446-1268-01

D-0396-2022
Recall number
D-0396-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
8140 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

10-2021-25@4 12/08/2021 11-2021-08@6 12/22/2021

Distribution pattern

nationwide

drug · product 4 of 56

Ceftazidime, Sterile Ophthalmic Solution for Injection, Preservative Free (11.25 mg/0.5 mL (22.5 mg/mL), 0.5mL single use syringe for Intraocular Injection, Edge Pharma, LLC, 656 Hercules Dr., Colchester, VT 05446, NDC 05446-0733-01

D-0397-2022
Recall number
D-0397-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
168 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-01@6 12/14/2021 & 10-2021-27@4 01/01/2022

Distribution pattern

nationwide

drug · product 5 of 56

Cefuroxime, Sterile Ophthalmic Solution for Injection, Preservative Free, 3mg/0.3mL (10 mg/mL), 0.3 mL single use syringe for Intraocular Injection, Edge Pharma, LLC, 656 Hercules Dr., Colchester, VT 05446 NDC 05446-1003-01

D-0398-2022
Recall number
D-0398-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1720 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-30@1 12/20/2021, 09-2021-21@5 01/03/2022 & 10-2021-18@5 02/07/2022

Distribution pattern

nationwide

drug · product 6 of 56

Dexamethasone sodium phosphate, sterile otic solution for injection Preservative free, 19.2 mg/0.8mL (24mg/mL), 0.8 mL per syringe Single Use Syringe For Otic Injection, Edge Pharma LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-0848-01

D-0399-2022
Recall number
D-0399-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
323 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-28@1 01/10/2022

Distribution pattern

nationwide

drug · product 7 of 56

Edetate Disodium (EDTA), Sterile Ophthalmic Solution (PF) 1.5%, 10 mL per dropper, Single Dose Droptainer for Topical Ophthalmic Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT, 05446, NDC 05446-1427-10

D-0400-2022
Recall number
D-0400-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
80 droppers

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility.

Code information

10-2021-20@1 02/10/2022

Distribution pattern

nationwide

drug · product 8 of 56

Edetate Disodium (EDTA), Sterile Ophthalmic Solution, (PF) 3%, 10mL per dropper, Single Dose Droptainer for Topical Ophthalmic Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT, 05446, NDC 05446-1428-10

D-0401-2022
Recall number
D-0401-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
Unavailable

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-22@1 01/04/2022

Distribution pattern

nationwide

drug · product 9 of 56

Epinephrine/Lidocaine HCl Sterile Ophthalmic Solution for Injection, Preservative Free, 0.025%/0.75%, 0.8 mL per syringe, Single Use Syringe, For Intraocular Injection, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT 05446, NDC 05446-0863-01

D-0402-2022
Recall number
D-0402-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
2568 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

10-2021-18@4 12/08/2021& 11-2021-01@3 12/22/2021

Distribution pattern

nationwide

drug · product 10 of 56

Gemcitabine, Sterile Intravesical Solution, Preservative Free, 1g/50mL (20 mg/mL), 50 mL per syringe, Single Dose Syringe for Intravesical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1566-50

D-0403-2022
Recall number
D-0403-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
627 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-18@1 12/14/2021, 08-2021-27@1 12/09/2021, 09-2021-01@4 12/14/2021, 09-2021-08@2 12/21/2021, 09-2021-14@6 01/05/2021, 09-2021-16@4 12/29/2021, 09-2021-17@4 12/30/2021, 09-2021-22@3 01/04/2022 & 10-2021-27@3 02/08/2022

Distribution pattern

nationwide

drug · product 11 of 56

Lidocaine HCL / Bupivacaine HCL (contains Hyaluronidase 15 units/mL), Sterile Ophthalmic Solution for Injection (PF), 2%/0.375%, 8 mL per syringe, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1548-18

D-0404-2022
Recall number
D-0404-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1202 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

10-2021-26@3 12/04/2021 11-2021-09@1 12/23/2021

Distribution pattern

nationwide

drug · product 12 of 56

Methacholine Challenge 5-Syringe Test Kit, Sterile Inhalation Solution, Preservative Free, 3 mL per syringe,(NDC 05446-1600-05), Kit includes; individual syringe: Methacholine Chloride,16 mg/mL (contains 48 mg) NDC 05446-1241-01; Methacholine Chloride 4 mg/mL (contains 12mg), NDC 05446-1246-01; Methacholine chloride 1mg/mL (contains 3 mg), NDC 05446-1247-01; Methacholine chloride 0.25mg/mL (contains 0.75mg), NDC 05446-1248-01; and Methacholine chloride 0.0625mg/mL NDC 05446-1249-01 Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446

D-0405-2022
Recall number
D-0405-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1007 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-03@6 12/16/2021 & 10-2021-06@7 01/18/2022

Distribution pattern

nationwide

drug · product 13 of 56

Methotrexate, USP, Sterile Solution for Injection (PF), 125 mg/5mL (2mg/mL), 5 mL per syringe, Edge Pharma, LLC, 856 Hercules Dr, Colchester, VT 05446, NDC 05446-1505-05

D-0406-2022
Recall number
D-0406-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
457 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-10@2 12/23/2021, 10-2021-21@2 02/01/2022 & 11-2021-09@5 02/21/2022

Distribution pattern

nationwide

drug · product 14 of 56

Mitomycin-C, 40mg/40mL (1mg/mL), 40 mL per syringe, Single Dose Syringe for Intravesical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1416-01

D-0407-2022
Recall number
D-0407-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
860 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-24@5 12/09/2021, 08-2021-27@2 12/21/2021, 08-2021-31@5 12/14/2021, 09-2021-02@2 12/15/2021, 09-2021-09@2 12/22/2021, 09-2021-15@3 12/29/2021, 09-2021-22@2 01/04/2022 & 10-2021-26@5 02/07/2022

Distribution pattern

nationwide

drug · product 15 of 56

Mitomycin-C Sterile Ophthalmic Solution, Preservative Free, 0.32mg/0.8 mL (0.4mg/mL) 0.8 mL per syringe, Single Use Syringe, For Topical Ophthalmic Use, Edge Pharma LLC, 856 Hercules Dr. Colchester, VT 05446, NDC 05446-1009-01

D-0408-2022
Recall number
D-0408-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
163 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

11-2021-08@8 12/18/2021

Distribution pattern

nationwide

drug · product 16 of 56

Mitomycin-C, Sterile Ophthalmic Solution, Preservative Free, 0.16mg/0.8mL (0.2 mg/mL), 0.8 mL per syringe, Single Use Syringe, For Topical Ophthalmic Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1011-01

D-0409-2022
Recall number
D-0409-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
154 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

11-2021-08@9 12/18/2021

Distribution pattern

nationwide

drug · product 17 of 56

Moxifloxacin, Sterile Ophthalmic Solution for Injection, Preservative Free, 0.8mg/0.8 mL (1mg/mL), 0.8 mL per syringe, Single Use Syringe, For Intraocular Injection, Edge Pharma, LL, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1050-01

D-0410-2022
Recall number
D-0410-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
860 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-26@2 12/09/2021 & 09-2021-23@1 01/05/2022

Distribution pattern

nationwide

drug · product 18 of 56

Neostigmine methylsulfate, 5 mg/5mL (1 mg/mL), 5 mL per syringe, Single Use Syringe for IV or IM Injection, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT 05446, NDC 05446-1549-05

D-0411-2022
Recall number
D-0411-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
160 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

10-2021-07@1 01/19/2022

Distribution pattern

nationwide

drug · product 19 of 56

MVASI, (bevacizumab-awwb), Sterile Ophthalmic Solution for Injection, 3.25mg/0.13mL (25 mg/mL) 0.13 mL per syringe, Dose: 1.25mg/0.05mL, Single Use Syringe For Intraocular Injection, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT 05446, NDC 05446-1661-13

D-0412-2022
Recall number
D-0412-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
199 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

11-2021-01@2 12/15/2021

Distribution pattern

nationwide

drug · product 20 of 56

Phenol, Sterile Solution for Injection (PF), 6%, 5 mL per vial, Single Use Vial for Perineural Injection, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1476-05, packaged in vials.

D-0413-2022
Recall number
D-0413-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
309 vials

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-14@5 12/29/2021, 10/21/21 & 11-2021-04@2, 02/15/2022

Distribution pattern

nationwide

drug · product 21 of 56

Phenylephrine HCl / Tropicamide / Ciprofloxcin / Ketorolac Sterile Ophthalmic Solution, 10%/1%/0.3%/0.125%, 0.8 mL per syringe, Single Use Syringe, For Topical Ophthalmic Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1270-01

D-0414-2022
Recall number
D-0414-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
2463 vials

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-31@8 12/21/2021 & 10-2021-13@1 01/19/2022

Distribution pattern

nationwide

drug · product 22 of 56

Phenylephrine HCl 0.5 mg/5mL, (0.1 mg/mL), 5 mL per syringe, Single Use Syringe for IV Injection, Edge Pharma, LLC, 856 Hercules Dr, Colchester, VT 05446, NDC 05446-1545-05

D-0415-2022
Recall number
D-0415-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
3747 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-09@4 12/22/2021 & 10-2021-14@1 01/26/2022

Distribution pattern

nationwide

drug · product 23 of 56

Phenylephrine HCl, 1mg/10mL (0.1mg/mL), 10 mL per syringe, Single Use Syringe for IV Injection, Edge Pharma, LLC, 856 Hercules Dr, Colchester, VT 05446 NDC 05446-1544-10

D-0416-2022
Recall number
D-0416-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
6535 vials

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-26@3 12/16/2021, 09-2021-16@5 12/29/2021, 10-2021-07@2 01/19/2022 & 10-2021-22@1 02/03/2022.

Distribution pattern

nationwide

drug · product 24 of 56

Phenylephrine HCl, Sterile Solution for Injection, (PF), 800 mcg/10mL (80 mcg/mL), Single Use Syringe for IV Injection, Edge Pharma, LLC 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1652-01

D-0417-2022
Recall number
D-0417-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
5335 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-27@4 12/09/2021, 09-2021-17@1 12/30/2021, 10-2021-15@1 01/27/2022 & 10-2021-28@1 02/09/2022

Distribution pattern

nationwide

drug · product 25 of 56

PHENYLephrine, 0.9% Sodium Chloride Injection, USP, 20 mg/250mL, (0.08 mg/mL), Single use bag for IV injection (Preservative Free), Rx Only, Edge Pharma, LLC, 856 Hercules Dr, Colchester, VT NDC 05446-1667-01

D-0418-2022
Recall number
D-0418-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
3930 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-24@6 12/06/2021, 08-2021-31@7 12/12/2021, 09-2021-07@3 12/21/2021, 10-2021-20@2 02/02/2022 & 10-2021-28@2 02/10/2022.

Distribution pattern

nationwide

drug · product 26 of 56

Phenylephrine HCl/Lidocaine, Sterile Ophthalmic Solution for Injection, Preservative Free, 1.5%/1%, 0.8mL per syringe, Single Use Syringe For Intraocular Injection, Edge Pharma LLC, 856 Hercules Dr, Colchester, VT 05446, NDC 05446-1118-01

D-0419-2022
Recall number
D-0419-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
2750 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-16@1 12/29/2021

Distribution pattern

nationwide

drug · product 27 of 56

Phenylephrine HCl/Tropicamide, Sterile Ophthalmic Solution, 2.5%/1%, 15 mL per dropper, Multiple Dose Droptainer for Topical Ophthalmic Use, Edge Pharma, LLC, 856 Colchester, VT 05446, NDC 05446-0815-01

D-0420-2022
Recall number
D-0420-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
363 droptainers

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-15@1 12/28/2021

Distribution pattern

nationwide

drug · product 28 of 56

Phenylephrine HCl/Tropicamide/Cyclopentolate HCl/Ketorolac Sterile Ophthalmic Solution, 2.5%/0.25%/0.25%/0.125%, 0.5 mL syringe, Single Use Syringe, For Topical Ophthalmic Use, NDC 05446-0993-01

D-0421-2022
Recall number
D-0421-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
2562 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-15@2 12/28/2021 & 11-2021-02@3 02/14/2022

Distribution pattern

nationwide

drug · product 29 of 56

Phenylephrine HCl/Tropicamide/Cyclopentolate HCl/ Ketorolac Sterile Ophthalmic Solution, 10%/ 0.25%/ 0.25%/0.125%, 10 mL per dropper, Multiple Dose Droptainer for Topical Ophthalmic Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT, NDC 05446-0859-03

D-0422-2022
Recall number
D-0422-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
40 droptainers

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

11-2021-02@2 12/16/2021

Distribution pattern

nationwide

drug · product 30 of 56

Betadine (povidone-iodine), Sterile Ophthalmic Solution, Preservative Free, 5% 0.5mL per syringe, Single Use Syringe, For Topical Ophthalmic Use, Edge Pharma, LLC, 656 Hercules Dr., Colchester, VT 05446, NDC 05446-1680-01

D-0423-2022
Recall number
D-0423-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1773 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

10-2021-25@5 12/09/2021

Distribution pattern

nationwide

drug · product 31 of 56

Vancomycin HCl, Sterile Ophthalmic Solution for Injection, Preservative Free, 8 mg/0.8mL (10 mg/mL) (vancomycin equivalent), 0.8 mL per syringe, Single Use Syringe, For Intraocular Injection, Edge Pharma LLC, 856 Hercules Dr., Colchester, VT, 05446, NDC 05446-0736-01

D-0424-2022
Recall number
D-0424-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
3360 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-31@2 12/12/2021 & 09-2021-20@4 01/02/2022

Distribution pattern

nationwide

drug · product 32 of 56

Vancomycin HCl in 0.9 % Sodium Chloride Injection, USP, 1,250 mg/250 mL, Single Use Bag for IV Injection (Preservative Free), 250 mL pre-filled bag, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1456-01

D-0425-2022
Recall number
D-0425-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1795 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-13@3 12/27/2021 & 09-2021-30@5 01/13/2022

Distribution pattern

nationwide

drug · product 33 of 56

Vancomycin HCl in 0.9% Sodium Chloride Injection, 1,500 mg/500 mL, USP, Single Use Bag for IV Injection (Preservative Free), 500 mL pre-filled bag, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1458-01

D-0426-2022
Recall number
D-0426-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1825 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

08-2021-26@4 12/08/2021 & 09-2021-21@3 01/04/2022

Distribution pattern

nationwide

drug · product 34 of 56

Vancomycin HCl in 0.9% Sodium Chloride Injection, USP, 1,750mg/500mL, Single Use Bag for IV Injection (Preservative Free), 500 mL pre-filled bag, Rx Only, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446 NDC 05446-1459-01

D-0427-2022
Recall number
D-0427-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
749 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of Assurance of Sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of Assurance of Sterility

Code information

09-2021-09@6 12/23/2021 & 10-2021-13@5 01/27/2022

Distribution pattern

nationwide

drug · product 35 of 56

BLT Topical Cream, Benzocaine/Lidocaine/Tetracaine, 20%/8%/4%, 60gm per jar, Multiple Dose Container For Topical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT, 05446, NDC 05446-1235-01

D-0428-2022
Recall number
D-0428-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1173 jars

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

06-2021-10@11 12-07-2021, 06-2021-10@9 12-07-2021, 06-2021-17@6 12-14-2021, 06-2021-17@7 12-14-2021, 06-2021-24@5 12-21-2021, 06-2021-24@8 12-21-2021, 07-2021-01@6 12-28-2021, 07-2021-01@7 12-28-2021, 07-2021-09@5 01-01-2022, 07-2021-09@6 01-05-2022, 07-2021-15@5 01-01-2022, 07-2021-15@6 01-01-2022, 07-2021-22@16 01-19-2022, 07-2021-22@8 01-01-2022, 07-2021-29@12 01-25-2022, 07-2021-29@24 01-25-2022, 08-2021-05@7 02-01-2022, 08-2021-05@8 02-01-2022, 08-2021-19@7 02-15-2022, 08-2021-19@8 02-15-2022, 08-2021-26@5 02-22-2022, 09-2021-01@10 02-28-2022, 09-2021-03@7 03-02-2022, 09-2021-09@7 03-08-2022, 09-2021-16@7 03-15-2022, 09-2021-17@7 03-16-2022, 09-2021-22@8 03-21-2021, 09-2021-23@2 03-22-2022, 09-2021-23@3 03-22-2022, 09-2021-30@10 03-29-2022, 09-2021-30@8 03-29-2022, 10-2021-07@10 04-05-2022, 10-2021-07@7 04-05-2022, 10-2021-08@1 04-06-2022, 10-2021-14@4 04-12-2022, 10-2021-14@5 04-12-2022, 10-2021-21@7 04-19-2022 & 10-2021-28@3 04-26-2022

Distribution pattern

nationwide

drug · product 36 of 56

Cantharidin Gel-Forming Suspension, 0.7%, 10 mL per vial, Multiple Dose Vial for Topical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05546 NDC 05446-0572-03

D-0429-2022
Recall number
D-0429-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1173 vials

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

06-2021-11@6 12-08-2021, 07-2021-08@13 01-04-2022, 08-2021-06@6 02-02-2022, 08-2021-20@10 02-16-2022, 08-2021-26@6 02-22-2022, 08-2021-27@7 02-23-2022, 09-2021-02@5 03-01-2022, 09-2021-17@8 03-16-2022 & 09-2021-29@12 03-28-2022

Distribution pattern

nationwide

drug · product 37 of 56

Cantharidin PLUS, Cantharidin/Salicylic Acid Gel-Forming Suspension, 10 mL per vial, Multiple Dose Vials for Topical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT, 05446, NDC 05446-0970-03

D-0430-2022
Recall number
D-0430-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
2204 vials

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

06-2021-09@9 12-06-2021, 06-2021-16@11 12-13-2021, 06-2021-23@7 12-20-2021, 06-2021-30@11 12-27-2021, 07-2021-07@9 01-03-2022, 07-2021-13@6 01-09-2021, 07-2021-14@5 01-10-2022, 07-2021-21@8 01-17-2022, 07-2021-26@10 01-22-2022, 08-2021-04@5 01-31-2022, 08-2021-09@11 02-05-2022, 08-2021-10@6 02-06-2022, 08-2021-17@5 02-13-2022, 08-2021-25@4 02-21-2022, 09-2021-01@8 02-28-2022, 09-2021-08@8 03-07-2022, 09-2021-15@6 03-14-2022, 09-2021-21@8 03-20-2022, 09-2021-27@10 03-26-2022, 10-2021-06@8 04-04-2022, 10-2021-13@7 04-11-2022, 10-2021-20@7 04-18-2022, 10-2021-20@9 04-18-2021 & 10-2021-26@9, 04-24-2022

Distribution pattern

nationwide

drug · product 38 of 56

CSF Otic Insufflation Capsule, Sulfacetamide Sodium/ Ciprofloxacin/ Amphotericin B Otic Powder, 50mg / 30mg / 5mg, 5 count bottle, For Otic Use with Insufflator, Edge Pharma, LLC 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1633-05

D-0431-2022
Recall number
D-0431-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1055 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

10-2021-27@8 01-25-2022

Distribution pattern

nationwide

drug · product 39 of 56

CSF-HC Otic Insufflation Capsule, Sulfacetamide Sodium/Ciprofloxacin/Hydrocortisone/Amphotericin B Otic Powder, 50mg/ 30mg/ 25mg/ 5mg, 5 count bottle, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1634-01

D-0432-2022
Recall number
D-0432-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
440 cartons

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

10-2021-05@9 01-01-2022 & 10-2021-28@4 01-26-2022

Distribution pattern

nationwide

drug · product 40 of 56

Dexamethasone sodium phosphate 0.4%, 120 mL per bottle, Multiple Dose Container For Topical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-0622-01

D-0433-2022
Recall number
D-0433-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
56 cartons

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

06-2021-23@6 12-20-2021, 09-2021-15@4 03-14-2022 & 10-2021-04@10 04-02-2022

Distribution pattern

nationwide

drug · product 41 of 56

Dibutyl Squaric Acid, Topical Solution (PF), Multiple Dose Vial, 2%, 10 mL per vial, Edge Pharma, LLC, 856 Hercules Dr, Colchester VT, 05446, NDC 05446-1047-03

D-0434-2022
Recall number
D-0434-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
63 vials

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

09-2021-15@5 12-14-2021 & 10-2021-01@4 12-30-2021

Distribution pattern

nationwide

drug · product 42 of 56

Dibutyl Squaric Acid, Topical Solution (PF) Multiple Dose Vial, 1%, 10 mL per vial, Edge Parma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1156-03

D-0435-2022
Recall number
D-0435-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
20 vials

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

08-2021-03@8 12-31-2021 & 09-2021-07@10 02-04-2022

Distribution pattern

nationwide

drug · product 43 of 56

LT Topical Cream, Lidocaine/Tetracaine, 23%/7%, 60gm per jar, Multiple Dose Container for Topical Use, Edge Pharma, LLC, 856 Hercules, VT, Colchester, VT 05446, NDC 05446-1647-01

D-0436-2022
Recall number
D-0436-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
74 jars

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

08-2021-23@9 02-19-2022, 09-2021-07@13 03-06-2022 & 10-2021-22@5 04-20-2022.

Distribution pattern

nationwide

drug · product 44 of 56

LET Topical Gel, Lidocaine HCL / Epinepherine / Tetracaine HCl, 4%/0.05%/0.5%, 3 mL per syringe, Single Dose Syringe for Topical Use, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT, NDC 05446-0607-01

D-0437-2022
Recall number
D-0437-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
26917 syringes

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

07-2021-12@6 12-09-2021, 07-2021-19@7 12-16-2021, 07-2021-26@5 12-23-2021, 08-2021-02@8 12-30-2021, 08-2021-09@10 01-06-2022, 08-2021-13@6 01-10-2022, 08-2021-18@4 01-15-2022, 08-2021-24@8 01-21-2022, 08-2021-30@5 01-27-2022, 09-2021-07@11 02-04-2022, 09-2021-13@5 02-10-2022 & 10-2021-04@9 03-03-2022.

Distribution pattern

nationwide

drug · product 45 of 56

Lidocaine HCl / Oxymetazoline HCl Nasal Solution, 4% / 0.05%, 240mL per bottle, Multiple Dose Container for Intranasal Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1256-01, packaged in bottles. no label

D-0438-2022
Recall number
D-0438-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
386 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

06-2021-18@3 12-15-2021 07/07/21 - 07/22/21 06-2021-30@10 12-27-2021 07/20/21 - 08/17/21 07-2021-14@4 01-10-2022 08/05/21 - 08/20/21 07-2021-21@4 01-17-2022 08/23/21 - 09/16/21, 07-2021-28@9 01-24-2022 09/13/21 - 10/05/21 08-2021-12@8 02-08-2022 10/01/21 - 10/19/21 08-2021-24@9 02-20-2022 10/19/21 - 11/11/21 09-2021-09@10 03-08-2022 11/10/21 - 11/30/21 10-2021-05@6 04-03-2022 11/30/21

Distribution pattern

nationwide

drug · product 46 of 56

Profound Dental Gel, Lidocaine HCl/Prilocaine HCl/Tetracaine HCl, 10%/10%/4% Raspberry Marshmallow, 30 grams per jar, Multiple Dose Container For Topical Oral Use,Edge Pharma LLC, 856 Hercules Dr. Colchester, VT 05446, NDC 05446-0790-10

D-0439-2022
Recall number
D-0439-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
353 jars

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

07-2021-20@7 01-16-2022, 08-2021-11@6 02-07-2022, 08-2021-31@11 02-01-2022, 09-2021-14@11 02-01-2022, 09-2021-21@6 02-01-2022 & 10-2021-12@4 04-10-2022.

Distribution pattern

nationwide

drug · product 47 of 56

Profound Dental Gel, Lidocaine HCl/Prilocaine HCl/Tetracaine HCl, 10% / 10% / 4%, Spearmint-Peppermint, Multiple Dose Container for Topical Oral Use, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT NDC 05446-0407-10

D-0440-2022
Recall number
D-0440-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
221 jars

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

08-2021-16@12 02-01-2022 09/21/21 - 10/19/21 09-2021-13@8 02-01-2022 11/04/21 - 11/17/21 09-2021-29@8 03-01-2022 10/18/21 - 11/11/21 10-2021-26@7 04-24-2022 11/17/21 - 12/01/21

Distribution pattern

nationwide

drug · product 48 of 56

Profound-PE Dental Gel, Lidocaine HCl/ Prilocaine HCl/ Tetracaine HCl/ Phenylephrin HCl, 10% / 10% / 4% / 2% Raspberry-Marshmallow, Multiple Dose Container for Topical Oral Use, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT NDC 05446-1018-10

D-0441-2022
Recall number
D-0441-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
418 jars

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

06-2021-29@15 12-26-2021, 07-2021-12@7 01-08-2022, 08-2021-03@7 01-30-2022, 08-2021-25@5 02-01-2022, 09-2021-10@4 02-01-2022, 09-2021-22@6 03-01-2022 & 10-2021-06@11 04-04-2022

Distribution pattern

nationwide

drug · product 49 of 56

Profound-PE Dental Gel, Lidocaine HCl/Prilocaine HCl/Tetracaine HCl/Phenylephrine, 10% / 10% / 4% / 2%, Spear-Peppermint, Multiple Dose Container for Topical Oral Use, 30 grams per jar, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT, 05446, NDC 05446-0408-10

D-0442-2022
Recall number
D-0442-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
175 jars

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

07-2021-13@7 01-09-2022 08/24/21 - 10/06/21 07-2021-27@8 01-23-2022 10/06/21 - 11/02/21 08-2021-10@5 02-01-2022 10/28/21 - 12/01/21

Distribution pattern

nationwide

drug · product 50 of 56

Phenol, Topical Solution (PF) Multiple Dose Vial, 89%, 3 mL per vial, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT, NDC 05446-1211-03

D-0443-2022
Recall number
D-0443-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
1861 jars

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

07-2021-12@9 01-08-2022 07/22/21 - 08/11/21 08-2021-11@10 02-07-2022 08/25/21 - 09/10/21 08-2021-12@12 02-08-2022 09/07/21 - 10/06/21 09-2021-22@5 03-21-2022 10/12/21 - 10/28/21 10-2021-07@8 04-05-2022 10/25/21 - 10/28/21 10-2021-08@4 04-06-2022 10/28/21 - 11/12/21 11-2021-01@7 04-30-2022 11/15/21 - 12/01/21

Distribution pattern

nationwide

drug · product 51 of 56

Lidocaine HCl/Phenylephrine HCl Nasal Solution, 4%/1%, 240 mL per bottle, Multiple Dose Container, Edge Pharma, LLC 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1045-03

D-0444-2022
Recall number
D-0444-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
231 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

07-2021-02@7 12-29-2021, 07-2021-23@4 01-19-2022, 08-2021-11@7 02-07-2022, 08-2021-23@8 02-19-2022 & 09-2021-24@10 03-23-2022

Distribution pattern

nationwide

drug · product 52 of 56

Vitamin K (Vitamin K ) Oral Solution (PF), 5 mg/mL, 1mL per syringe, single Dose Syringe for Oral Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1132-03

D-0445-2022
Recall number
D-0445-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
757 syringes

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

10-2021-11@6 01-09-2022 10/27/21 - 11/16/21 11-2021-01@8 01-30-2022 11/16/21 - 12/01/21

Distribution pattern

nationwide

drug · product 53 of 56

Promethazine HCl Topical Ointment, 2.5% (25 mg/mL), 1.2 mL per syringe, Single Dose Syreinge for Topical Use Only, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1341-01

D-0446-2022
Recall number
D-0446-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
7788 syringes

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

08-2021-02@9 12-15-2021, 08-2021-16@10 12-29-2021, 09-2021-08@6 01-21-2022, 09-2021-20@6 02-02-2022 & 10-2021-18@6 03-02-2022

Distribution pattern

nationwide

drug · product 54 of 56

Tetracaine HCl Nasal Solution, 4%, 240 mL per bottle, Multiple Dose Container for Intranasal Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT, 05446, NDC 05446-1195-03, packaged in bottles.

D-0447-2022
Recall number
D-0447-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
114 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

06-2021-08@5 12-05-2021, 07-2021-07@7 01-03-2022, 07-2021-27@10 01-23-2022 & 10-2021-06@12 04-04-2022

Distribution pattern

nationwide

drug · product 55 of 56

Vancomycin HCl Oral Solution (PF) 125mg / 2.5mL (50 mg/mL), 2.5 mL per syringe, Single Dose Syringe for Oral Use Only, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1348-01

D-0448-2022
Recall number
D-0448-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
6925 syringes

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

09-2021-10@3 12-09-2021, 09-2021-17@6 12-16-2021, 09-2021-24@8 12-23-2021, 09-2021-30@7 12-29-2021 & 10-2021-13@6 01-11-2022 .

Distribution pattern

nationwide

drug · product 56 of 56

Trypan Blue 0.03%, 0.5mL per syringe, Sterile Ophthalmic Solution for Injection Preservative Free, Single Use Syringe, For Intraocular Injection, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1348-01

D-0449-2022
Recall number
D-0449-2022
Initiated
December 06, 2021
Classification
Class II
Status
Terminated
Recalling firm
Edge Pharma, LLC
Quantity
Unavailable

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
CGMP Deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

CGMP Deviations

Code information

09-2021-10@3 12-09-2021, 09-2021-17@6 12-16-2021, 09-2021-24@8 12-23-2021, 09-2021-30@7 12-29-2021 & 10-2021-13@6 01-11-2022 .

Distribution pattern

nationwide